155 related articles for article (PubMed ID: 29045509)
1. The antibody-drug conjugate target landscape across a broad range of tumour types.
Moek KL; de Groot DJA; de Vries EGE; Fehrmann RSN
Ann Oncol; 2017 Dec; 28(12):3083-3091. PubMed ID: 29045509
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
Bosi C; Bartha Á; Galbardi B; Notini G; Naldini MM; Licata L; Viale G; Mariani M; Pistilli B; Ali HR; André F; Piras M; Callari M; Barreca M; Locatelli A; Viganò L; Criscitiello C; Pusztai L; Curigliano G; Győrffy B; Dugo M; Bianchini G
Eur J Cancer; 2023 Dec; 195():113379. PubMed ID: 37913680
[TBL] [Abstract][Full Text] [Related]
3. The target atlas for antibody-drug conjugates across solid cancers.
Fang J; Guo L; Zhang Y; Guo Q; Wang M; Wang X
Cancer Gene Ther; 2024 Feb; 31(2):273-284. PubMed ID: 38129681
[TBL] [Abstract][Full Text] [Related]
4. Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates.
Nieto-Jiménez C; Sanvicente A; Díaz-Tejeiro C; Moreno V; Lopez de Sá A; Calvo E; Martínez-López J; Pérez-Segura P; Ocaña A
Clin Transl Med; 2023 Sep; 13(9):e1329. PubMed ID: 37740463
[TBL] [Abstract][Full Text] [Related]
5. Elucidating Novel Targets for Ovarian Cancer Antibody-Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity.
Onyido EK; James D; Garcia-Parra J; Sinfield J; Moberg A; Coombes Z; Worthington J; Williams N; Francis LW; Conlan RS; Gonzalez D
Antibodies (Basel); 2023 Oct; 12(4):. PubMed ID: 37873862
[TBL] [Abstract][Full Text] [Related]
6. Computational selection of antibody-drug conjugate targets for breast cancer.
Fauteux F; Hill JJ; Jaramillo ML; Pan Y; Phan S; Famili F; O'Connor-McCourt M
Oncotarget; 2016 Jan; 7(3):2555-71. PubMed ID: 26700623
[TBL] [Abstract][Full Text] [Related]
7. Data-Driven Discovery of Molecular Targets for Antibody-Drug Conjugates in Cancer Treatment.
Razzaghdoust A; Rahmatizadeh S; Mofid B; Muhammadnejad S; Parvin M; Torbati PM; Basiri A
Biomed Res Int; 2021; 2021():2670573. PubMed ID: 33490264
[TBL] [Abstract][Full Text] [Related]
8. Progress of antibody-drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies.
Mer AH; Mirzaei Y; Misamogooe F; Bagheri N; Bazyari A; Keshtkaran Z; Meyfour A; Shahedi A; Amirkhani Z; Jafari A; Barpour N; Jahandideh S; Rezaei B; Nikmanesh Y; Abdollahpour-Alitappeh M
Drug Deliv Transl Res; 2024 Apr; ():. PubMed ID: 38597995
[TBL] [Abstract][Full Text] [Related]
9. Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis.
Li J; Shen G; Liu Z; Liu Y; Wang M; Zhao F; Ren D; Xie Q; Li Z; Liu Z; Zhao Y; Ma F; Liu X; Xu Z; Zhao J
Cancer Innov; 2023 Oct; 2(5):346-375. PubMed ID: 38090386
[TBL] [Abstract][Full Text] [Related]
10. Expression of Potential Antibody-Drug Conjugate Targets in Cervical Cancer.
Mallmann MR; Tamir S; Alfter K; Ratiu D; Quaas A; Domroese CM
Cancers (Basel); 2024 May; 16(9):. PubMed ID: 38730739
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review.
Perrotti V; Caponio VCA; Mascitti M; Lo Muzio L; Piattelli A; Rubini C; Capone E; Sala G
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206707
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry of Lung Cancer Biomarkers.
Beasley MB
Adv Anat Pathol; 2024 Apr; ():. PubMed ID: 38666761
[TBL] [Abstract][Full Text] [Related]
13. Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine.
Nössing C; Herek P; Shariat SF; Berger W; Englinger B
Curr Opin Urol; 2024 Apr; ():. PubMed ID: 38602053
[TBL] [Abstract][Full Text] [Related]
14. The antibody-drug conjugate landscape.
Flynn P; Suryaprakash S; Grossman D; Panier V; Wu J
Nat Rev Drug Discov; 2024 Apr; ():. PubMed ID: 38627573
[No Abstract] [Full Text] [Related]
15. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
[TBL] [Abstract][Full Text] [Related]
16. Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends.
Drake PM; Rabuka D
BioDrugs; 2017 Dec; 31(6):521-531. PubMed ID: 29119409
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
Nagayama A; Ellisen LW; Chabner B; Bardia A
Target Oncol; 2017 Dec; 12(6):719-739. PubMed ID: 29116596
[TBL] [Abstract][Full Text] [Related]
18. Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors.
Staben LR; Yu SF; Chen J; Yan G; Xu Z; Del Rosario G; Lau JT; Liu L; Guo J; Zheng B; Cruz-Chuh JD; Lee BC; Ohri R; Cai W; Zhou H; Kozak KR; Xu K; Lewis Phillips GD; Lu J; Wai J; Polson AG; Pillow TH
ACS Med Chem Lett; 2017 Oct; 8(10):1037-1041. PubMed ID: 29057047
[TBL] [Abstract][Full Text] [Related]
19. Macrocyclic pyrrolobenzodiazepine dimers as antibody-drug conjugate payloads.
Donnell AF; Zhang Y; Stang EM; Wei DD; Tebben AJ; Perez HL; Schroeder GM; Pan C; Rao C; Borzilleri RM; Vite GD; Gangwar S
Bioorg Med Chem Lett; 2017 Dec; 27(23):5267-5271. PubMed ID: 29102228
[TBL] [Abstract][Full Text] [Related]
20. A Versatile Chemo-Enzymatic Conjugation Approach Yields Homogeneous and Highly Potent Antibody-Drug Conjugates.
Xu Y; Jin S; Zhao W; Liu W; Ding D; Zhou J; Chen S
Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29088062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
